AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18049097 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 28
Study 18049097 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-DTPA clearance
Number of subjects: 28
Study 16865577 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen/progestin
Number of subjects: 31
Study 16865577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16865577 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen/progestin and Placebo
Number of subjects: 31
Study 12771325 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignan intake (173 microg/d for men, 151 microg/d for women)
Number of subjects: 2852
Study 11128344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 150 mg/daily
Number of subjects: 17
Study 11128344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9097868 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naltrexone (100 mg bid) followed by 200 mg bid during open-label period
Number of subjects: 0
Study 8460346 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐streptococci
Number of subjects: 36
Study 8460346 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 3539851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (PG)
Number of subjects: 112
Study 3539851 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic systemic antibiotics (PSA)
Number of subjects: 112
Study 30541563 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Loyalty Scheme (PAL) intervention involving rewards for increasing physical activity; participants earned points for minutes of activity that could be redeemed for rewards, complemented by evidence-based behaviour change techniques.
Number of subjects: 853
Study 30541563 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Loyalty Scheme (PAL) intervention
Number of subjects: 853
Study 30541563 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list controlled)
Number of subjects: 853
Study 26598744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib + Trastuzumab (L+T)
Number of subjects: 8381
Study 26598744 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab followed by Lapatinib (T->L)
Number of subjects: 8381
Study 26598744 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (T)
Number of subjects: 8381
Study 23887684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication followed by intraoperative saline infusion (group A)
Number of subjects: 74
Study 23887684 — intervention group
Group type: COMPARATOR
Intervention: Placebo premedication followed by dexmedetomidine infusion (group B)
Number of subjects: 74
Study 23887684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (clonidine and dexmedetomidine)
Number of subjects: 74
Study 23948783 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 90
Study 23948783 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan
Number of subjects: 90
Study 23948783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 90
Study 23948783 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study 21244668 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Education Pulmonary Rehabilitation Programme (SEPRP) delivered by practice nurses and physiotherapists
Number of subjects: 320
Study 21244668 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 18438247 — intervention group
Group type: EXPERIMENTAL
Intervention: VertiMax training group
Number of subjects: 64
Study 18438247 — intervention group
Group type: COMPARATOR
Intervention: Training control group
Number of subjects: 64
Study 17154731 — intervention group
Group type: EXPERIMENTAL
Intervention: toddler-parent psychotherapy (DI)
Number of subjects: 130
Study 17154731 — intervention group
Group type: COMPARATOR
Intervention: control group (DC)
Number of subjects: 130
Study 17154731 — intervention group
Group type: COMPARATOR
Intervention: nondepressed comparison group (NC)
Number of subjects: 130
Study 12687826 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial lead positions in physiological pacing (RA free wall, RA appendage, near coronary sinus ostium, dual site RA pacing)
Number of subjects: 0
Study 11017811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 60 mg/day for 2 weeks
Number of subjects: 110
Study 11017811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 9251115 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic intra-arterial (HIA) chemotherapy
Number of subjects: 0
Study 9251115 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study 9251115 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 1609034 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment with 50% dose decrease
Number of subjects: 24
Study 1609034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3303753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of MTX and 5-FU (therapy arm A)
Number of subjects: 43
Study 3303753 — intervention group
Group type: COMPARATOR
Intervention: Systematic treatment with CMFV combination (therapy arm B)
Number of subjects: 43
Study 29544607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7213
Study 29544607 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 7213
Study 29544607 — intervention group
Group type: COMPARATOR
Intervention: UFH with GPI
Number of subjects: 7213
Study 27169702 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 pain scale (pain intensity and pain interference)
Number of subjects: 1447
Study 27169702 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30
Number of subjects: 1447
Study 27169702 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 pain intensity item
Number of subjects: 1447
Study 27169702 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 pain scale
Number of subjects: 1447
Study 27169702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain experience and pain burden
Number of subjects: 1447
Study 25007368 — intervention group
Group type: EXPERIMENTAL
Intervention: Luliconazole cream 1%
Number of subjects: 321
Study 25007368 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 321
Study 22698293 — intervention group
Group type: EXPERIMENTAL
Intervention: Small titanium plates
Number of subjects: 127
Study 22698293 — intervention group
Group type: COMPARATOR
Intervention: Large titanium plates
Number of subjects: 127
Study 20332720 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol injection to the motor branches of tibial nerve
Number of subjects: 20
Study 20332720 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol injection to the motor branches of tibial nerve
Number of subjects: 20
Study 17972162 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare Metal Stent (BMS)
Number of subjects: 20
Study 17972162 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 20
Study 16607468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (1.5 to 4.5 mg/day)
Number of subjects: 67
Study 16607468 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50 mg/day)
Number of subjects: 67
Study 14615578 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant (nefazodone)
Number of subjects: 681
Study 14615578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 681
Study 14615578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antidepressant and psychotherapy
Number of subjects: 681
Study 14615578 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy alone
Number of subjects: 681
Study 14615578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and pharmacotherapy
Number of subjects: 681
Study 10524470 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone given every 12 hours
Number of subjects: 57
Study 10524470 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxycodone given four times daily
Number of subjects: 57
Study 7676793 — intervention group
Group type: EXPERIMENTAL
Intervention: 24G Sprotte needle
Number of subjects: 200
Study 7676793 — intervention group
Group type: COMPARATOR
Intervention: 27G Quincke needle
Number of subjects: 200
Study 1975246 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blockers
Number of subjects: 0
Study 1975246 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 1975246 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers with concurrent alpha-blocker
Number of subjects: 0
Study 1975246 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (enalapril)
Number of subjects: 0
Study 1975246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7009255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg daily)
Number of subjects: 74
Study 7009255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 31411768 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 μg daily (subcutaneous injection) for 18 months followed by alendronate 70 mg once weekly for up to 24 months
Number of subjects: 0
Study 31411768 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by alendronate 70 mg once weekly for up to 24 months
Number of subjects: 0
Study 28719669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (SUPP; n = 25; 30 g whey protein, 2.5 g creatine, 500 IU vitamin D, 400 mg calcium, 1500 mg n‐3 PUFA)
Number of subjects: 49
Study 28719669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (SUPP + EX)
Number of subjects: 49
Study 28719669 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; n = 24; 22 g of maltodextrin)
Number of subjects: 49
Study 28719669 — intervention group
Group type: COMPARATOR
Intervention: Control (CON + EX)
Number of subjects: 49
Study 26505596 — intervention group
Group type: COMPARATOR
Intervention: LABA + ICS
Number of subjects: 1070
Study 26505596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + ICS
Number of subjects: 1070
Study 23474882 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging-based education and behavioral support for 14 days
Number of subjects: 43
Study 23474882 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving text-message support)
Number of subjects: 43
Study 21536612 — intervention group
Group type: EXPERIMENTAL
Intervention: First exposure to high altitude (3450 m)
Number of subjects: 56
Study 21536612 — intervention group
Group type: EXPERIMENTAL
Intervention: Second exposure to high altitude (3450 m)
Number of subjects: 56
Study 21536612 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AMS incidence between adults and children
Number of subjects: 56
Study 21536612 — intervention group
Group type: COMPARATOR
Intervention: Intraindividual reproducibility of AMS
Number of subjects: 56
Study 21536612 — intervention group
Group type: COMPARATOR
Intervention: AMS predictive value based on history
Number of subjects: 56
Study 18973934 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 4
Study 16400043 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced portion size (25% decrease)
Number of subjects: 24
Study 16400043 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced energy density (25% decrease)
Number of subjects: 24
Study 16400043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined reduction in portion size and energy density
Number of subjects: 24
Study 16400043 — intervention group
Group type: COMPARATOR
Intervention: Control (standard portion size and energy density)
Number of subjects: 24
Study 15252005 — intervention group
Group type: EXPERIMENTAL
Intervention: League tables
Number of subjects: 122
Study 15252005 — intervention group
Group type: COMPARATOR
Intervention: Control charts
Number of subjects: 122
Study 11760164 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin (200 mg/d)
Number of subjects: 527
Study 11760164 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g/d; with or without erythromycin)
Number of subjects: 527
Study 11760164 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin
Number of subjects: 527
Study 11760164 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 527
Study 9408806 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20 mg/day) plus placebo for 4 weeks
Number of subjects: 63
Study 9408806 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) plus pindolol (7.5 mg/day) for 1 week and placebo for 3 weeks
Number of subjects: 63
Study 9408806 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) plus pindolol (7.5 mg/day) for 4 weeks
Number of subjects: 63
Study 9408806 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) plus metoprolol (50 mg/day)
Number of subjects: 63
Study 8280499 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) education programme
Number of subjects: 193000
Study 8280499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BSE education)
Number of subjects: 193000
Study 3696921 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoluble task
Number of subjects: 66
Study 3696921 — intervention group
Group type: COMPARATOR
Intervention: Solvable task
Number of subjects: 66
Study 3696921 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial Action Coding System
Number of subjects: 66
Study 3696921 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrugator responses
Number of subjects: 66
Study 3696921 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrugator response activity
Number of subjects: 66
Study 31570114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention promoting fruit and vegetable consumption
Number of subjects: 225
Study 31570114 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study 29452599 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 to 6 weeks' pre-operative exercise programme
Number of subjects: 20
Study 29452599 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 20
Study 27310522 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-stable collagen matrix (VCMX)
Number of subjects: 20
Study 27310522 — intervention group
Group type: COMPARATOR
Intervention: Autogenous subepithelial connective tissue graft (SCTG)
Number of subjects: 20
Study 23772856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM), 750 mg, two doses, 1 week apart (Group A)
Number of subjects: 1011
Study 23772856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM), 750 mg, two doses, 1 week apart (Group C)
Number of subjects: 1011
Study 23772856 — intervention group
Group type: COMPARATOR
Intervention: Oral iron, 325 mg, 3 times a day for 14 days (Group B)
Number of subjects: 1011
Study 23772856 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care IV iron (Group D)
Number of subjects: 1011
Study 23772856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 1011
Study 23772856 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care IV iron
Number of subjects: 1011
Study 22962287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense intermittent exercise (24 bouts of 1 min cycling at 316 ± 19 W, 3 times per week for 4 weeks)
Number of subjects: 9
Study 22962287 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise
Number of subjects: 9
Study 22962287 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of high-intensity training
Number of subjects: 9
Study 20705778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (UG) with 1.5% mepivacaine, starting dose 13 mL for median nerve
Number of subjects: 0
Study 20705778 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation (NS) with 1.5% mepivacaine, starting dose 11 mL for ulnar nerve
Number of subjects: 0
Study 19117154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% + sufentanil 0.75 microg mL‐1 (Group-I)
Number of subjects: 50
Study 19117154 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% (Group-II)
Number of subjects: 50
Study 16600560 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term pre-operative radiotherapy
Number of subjects: 0
Study 12544181 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.60 mg/kg methylphenidate
Number of subjects: 24
Study 12544181 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg/kg methylphenidate
Number of subjects: 24
Study 10573560 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable diet
Number of subjects: 56
Study 8935018 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac
Number of subjects: 52
Study 8935018 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivicaine with 1:20 K levonordefrin
Number of subjects: 52
Study 8935018 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study 1927953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 54
Study 1927953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 6614894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 157
Study 6614894 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 157
Study 6614894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (after excluding high levels)
Number of subjects: 157
Study 6614894 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (after excluding high levels)
Number of subjects: 157
Study 31944576 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) for at least 3 minutes
Number of subjects: 17
Study 31944576 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (historical control)
Number of subjects: 17
Study 31083015 — intervention group
Group type: EXPERIMENTAL
Intervention: A-mode ultrasound (US)
Number of subjects: 43
Study 29703242 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth program
Number of subjects: 110
Study 29703242 — intervention group
Group type: COMPARATOR
Intervention: usual care supervised health program
Number of subjects: 110
Study 27039381 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training during hospitalization and after discharge (home-based)
Number of subjects: 80
Study 27039381 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 23943850 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride (150 mg)
Number of subjects: 56
Study 23943850 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant to antimalarial treatment (Control)
Number of subjects: 56
Study 22997691 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 34
Study 22997691 — intervention group
Group type: COMPARATOR
Intervention: Control group (unchanged or deteriorated)
Number of subjects: 34
Study 20729270 — intervention group
Group type: EXPERIMENTAL
Intervention: DESMOND intervention
Number of subjects: 0
Study 20729270 — intervention group
Group type: EXPERIMENTAL
Intervention: DESMOND intervention (using 'real world' costs)
Number of subjects: 0
Study 17701094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluoride dose (≤20 mg fluoride equivalents)
Number of subjects: 25
Study 17701094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride treatment
Number of subjects: 25
Study 17701094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride treatment with daily dose >20 mg fluoride equivalents
Number of subjects: 25
Study 15899105 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marketing surveillance studies
Number of subjects: 0
Study 15899105 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marketing pharmacovigilance
Number of subjects: 0
Study 15899105 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marketing surveillance (PMS) studies
Number of subjects: 0
Study 12803658 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization with controlled detachable coils
Number of subjects: 0
Study 12803658 — intervention group
Group type: COMPARATOR
Intervention: Early coiling
Number of subjects: 0
Study 12803658 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (clipping)
Number of subjects: 0
Study 9723299 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 0
Study 9723299 — intervention group
Group type: EXPERIMENTAL
Intervention: Prograf
Number of subjects: 0
Study 9723299 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 0
Study 7912947 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia with fentanyl (4 micrograms kg‐1 bolus followed by 1 microgram kg‐1 h‐1 infusion)
Number of subjects: 30
Study 7912947 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1.1% end‐tidal)
Number of subjects: 30
Study 7912947 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia with thiopentone
Number of subjects: 30
Study 7912947 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with thiopentone
Number of subjects: 30
Study 7912947 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia with fentanyl
Number of subjects: 30
Study 7912947 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 2598976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg i.v.
Number of subjects: 10
Study 2598976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29153299 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 86
Study 29153299 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 27879582 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide expanders
Number of subjects: 150